Skip to main content

Table 2 The demographic and clinical characteristics of patients with HT in PTC background

From: Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis

Variables

PTC (n = 112)

P

HT absence (n = 77)

HT presence (n = 35)

Age (year, mean ± sd)

43.64 ± 11.49

42.06 ± 13.76

0.528

Gender [n(%)]

  

0.751

 Male

9 (11.69%)

3 (8.60%)

 

 Female

68 (88.31%)

32 (91.40%)

 

Tumor size (cm, mean ± sd)

1.28 ± 0.72

1.09 ± 0.50

0.161

Multifocality [n(%)]

  

0.674

 Positive

27 (35.06%)

14 (40.00%)

 

 Negative

50 (64.94%)

21 (60.00%)

 

TSH (mIU/L, mean ± sd)

2.43 ± 1.45

3.11 ± 1.75

0.034

Anti-TGAb

24.27 ± 13.55

173.17 ± 137.53

< 0.001

TPO-Ab

38.26 ± 15.57

525.44 ± 533.05

< 0.001

Extrathyroidal extension [n(%)]

  

0.172

 Positive

23 (29.87%)

6 (17.14%)

 

 Negative

54 (70.13%)

29 (82.86%)

 

CLNM [n(%)]

  

0.834

 Positive

30 (38.96%)

15 (42.86%)

 

 Negative

47 (61.04%)

20 (57.14%)

 

TNM stage 8th [n(%)]

  

0.533

 I, II

76 (98.68%)

34 (97.14%)

 

 III, IV

1 (1.32%)

1 (2.86%)

 
  1. PTC Papillary thyroid carcinoma, HT Hashimoto’s thyroiditis, TSH Thyroid stimulating hormone, anti-TGAb Antithyroglobulin antibody, TPO-Ab Thyroid peroxidase antibody, CLNM Central compartment lymph node metastasis, TNM Tumor node metastasis